Chlorpromazine N-oxide| CAS# 1672-76-0

MedKoo Cat#: 412108 | Name: Chlorpromazine N-oxide

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Chlorpromazine N-oxide is an organochlorine compound that has a role as a metabolite.

Chemical Structure

Chlorpromazine N-oxide

CAS#1672-76-0

Theoretical Analysis

MedKoo Cat#: 412108

Name: Chlorpromazine N-oxide

CAS#: 1672-76-0

Chemical Formula: C17H19ClN2OS

Exact Mass: 334.0907

Molecular Weight: 334.86

Elemental Analysis: C, 60.98; H, 5.72; Cl, 10.59; N, 8.37; O, 4.78; S, 9.57

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Chlorpromazine N-oxide; Ba2836; Ba-2836; Ba 2836

IUPAC/Chemical Name

10H-Phenothiazine-10-propanamine, 2-chloro-N,N-dimethyl-, N-oxide

InChi Key

SUQUPCVMBMERJG-UHFFFAOYSA-N

InChi Code

InChI=1S/C17H19ClN2OS/c1-19(2)10-5-11-20(21)14-6-3-4-7-16(14)22-17-9-8-13(18)12-15(17)20/h3-4,6-9,12H,5,10-11H2,1-2H3

SMILES Code

CN(C)CCC[N+]1([O-])C2=C(C=CC=C2)SC3=CC=C(Cl)C=C13

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 334.86 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Chetty M, Gouws E, Miller R, Moodley SV. The use of a side effect as a qualitative indicator of plasma chlorpromazine levels. Eur Neuropsychopharmacol. 1999 Jan;9(1-2):77-82. doi: 10.1016/s0924-977x(98)00005-4. PMID: 10082231. 2: Chetty M, Pillay VL, Moodley SV, Miller R. Response in chronic schizophrenia correlated with chlorpromazine, 7-OH-chlorpromazine and chlorpromazine sulfoxide levels. Eur Neuropsychopharmacol. 1996 May;6(2):85-91. doi: 10.1016/0924-977x(95)00047-s. PMID: 8791032. 3: Zhang D, Freeman JP, Sutherland JB, Walker AE, Yang Y, Cerniglia CE. Biotransformation of chlorpromazine and methdilazine by Cunninghamella elegans. Appl Environ Microbiol. 1996 Mar;62(3):798-803. doi: 10.1128/AEM.62.3.798-803.1996. PMID: 8975609; PMCID: PMC167846. 4: Muralidharan G, Cooper JK, Hawes EM, Korchinski ED, Midha KK. Quinidine inhibits the 7-hydroxylation of chlorpromazine in extensive metabolisers of debrisoquine. Eur J Clin Pharmacol. 1996;50(1-2):121-8. doi: 10.1007/s002280050079. PMID: 8739822. 5: Sato S, Koshiro A. Protein binding of chlorpromazine in vivo and in vitro: effect of chlorpromazine metabolite on chlorpromazine protein binding in rat. Biol Pharm Bull. 1995 Apr;18(4):586-92. doi: 10.1248/bpb.18.586. PMID: 7655433. 6: Chetty M, Moodley SV, Miller R. Important metabolites to measure in pharmacodynamic studies of chlorpromazine. Ther Drug Monit. 1994 Feb;16(1):30-6. doi: 10.1097/00007691-199402000-00004. PMID: 8160251. 7: Jaworski TJ, Sardessai MS, Aravagiri M, Lin G, Shi YY, Hawes EM, Hubbard JW, McKay G, Midha KK. Synthesis of the N-oxides of phenothiazine antipsychotic agents. J Pharm Sci. 1993 Mar;82(3):330-3. doi: 10.1002/jps.2600820323. PMID: 8095544. 8: Jaworski TJ, Hawes EM, Hubbard JW, McKay G, Midha KK. The metabolites of chlorpromazine N-oxide in rat bile. Xenobiotica. 1991 Nov;21(11):1451-9. doi: 10.3109/00498259109044395. PMID: 1763519. 9: Chetty M, Miller R. Effect of storage on the plasma concentration of chlorpromazine and six of its metabolites. Ther Drug Monit. 1991 Jul;13(4):350-5. doi: 10.1097/00007691-199107000-00012. PMID: 1780969. 10: Jaworski TJ, Hawes EM, McKay G, Midha KK. The metabolism of chlorpromazine N-oxide in man and dog. Xenobiotica. 1990 Jan;20(1):107-15. doi: 10.3109/00498259009046817. PMID: 2327102. 11: Jaworski TJ, Hawes EM, McKay G, Midha KK. The metabolism of chlorpromazine N-oxide in the rat. Xenobiotica. 1988 Dec;18(12):1439-47. doi: 10.3109/00498258809042266. PMID: 3266695. 12: Yeung PK, Hubbard JW, Korchinski ED, Midha KK. Radioimmunoassay for the N-oxide metabolite of chlorpromazine in human plasma and its application to a pharmacokinetic study in healthy humans. J Pharm Sci. 1987 Oct;76(10):803-8. doi: 10.1002/jps.2600761011. PMID: 3430345. 13: Midha KK, Hubbard JW, Cooper JK, Gurnsey T, Hawes EM, McKay G, Chakraborty BS, Yeung PK. Therapeutic monitoring of chlorpromazine. IV: Comparison of a new high-performance liquid chromatographic method with radioimmunoassays for parent drug and some of its major metabolites. Ther Drug Monit. 1987 Sep;9(3):358-65. PMID: 3672582. 14: Hawes EM, Hubbard JW, Martin M, McKay G, Yeung PK, Midha KK. Therapeutic monitoring of chlorpromazine. III: Minimal interconversion between chlorpromazine and metabolites in human blood. Ther Drug Monit. 1986;8(1):37-41. PMID: 3961895. 15: McKay G, Cooper JK, Hawes EM, Hubbard JW, Martin M, Midha KK. Therapeutic monitoring of chlorpromazine II: Pitfalls in whole blood analysis. Ther Drug Monit. 1985;7(4):472-7. doi: 10.1097/00007691-198512000-00020. PMID: 4082244. 16: Hubbard JW, Cooper JK, Hawes EM, Jenden DJ, May PR, Martin M, McKay G, Van Putten T, Midha KK. Therapeutic monitoring of chlorpromazine I: Pitfalls in plasma analysis. Ther Drug Monit. 1985;7(2):222-8. doi: 10.1097/00007691-198506000-00015. PMID: 4024218. 17: Krieglstein J, Rieger H, Schütz H. Effects of chlorpromazine and some of its metabolites on the EEG and on dopamine metabolism of the isolated perfused rat brain. Eur J Pharmacol. 1979 Jul 1;56(4):363-70. doi: 10.1016/0014-2999(79)90267-x. PMID: 477730. 18: Curry SH, Evans S. A note on the assay of chlorpromazine N-oxide and its sulphoxide in plasma and urine. J Pharm Pharmacol. 1976 May;28(5):467-8. doi: 10.1111/j.2042-7158.1976.tb04664.x. PMID: 6768. 19: Harinath BC, Odell GV. Chlorpromazine-N-oxide formation by subcellular liver fractions. Biochem Pharmacol. 1968 Jan;17(1):167-71. doi: 10.1016/0006-2952(68)90172-x. PMID: 4384243. 20: FISHMAN V, HEATON A, GOLDENBERG H. Metabolism of chlorpromazine. III. Isolation and identification of chlorpromazine-N-oxide. Proc Soc Exp Biol Med. 1962 Mar;109:548-52. doi: 10.3181/00379727-109-27264. PMID: 13893306.